Emil MD - Calithera Biosciences Chief Officer
| CALADelisted Stock | USD 0.05 0.00 0.00% |
Insider
Emil MD is Chief Officer of Calithera Biosciences
| Age | 43 |
| Phone | 650 870-1000 |
| Web | www.calithera.com |
Calithera Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.5629) % which means that it has lost $0.5629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1414) %, meaning that it created substantial loss on money invested by shareholders. Calithera Biosciences' management efficiency ratios could be used to measure how well Calithera Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Calithera Biosciences currently holds 1.67 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Calithera Biosciences has a current ratio of 4.72, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Calithera Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Calithera Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Calithera Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Calithera to invest in growth at high rates of return. When we think about Calithera Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| Sean Flynn | Verastem | 50 | |
| BPHARM RPh | Verastem | 63 | |
| Doron Cohen | Galmed Pharmaceuticals | 57 | |
| Christine Rothe | Pieris Pharmaceuticals | N/A | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Liat Hayardeny | Galmed Pharmaceuticals | 57 | |
| Joanna Brewer | Adaptimmune Therapeutics Plc | 48 | |
| Scott Santiamo | Abeona Therapeutics | N/A | |
| Christine CPA | Mereo BioPharma Group | 43 | |
| Juli Miller | Adaptimmune Therapeutics Plc | N/A | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Piyush Gupta | Verastem | N/A | |
| Hitto Kaufmann | Pieris Pharmaceuticals | 53 | |
| Michelle MD | Verastem | 48 | |
| Robert Weinberg | Verastem | N/A | |
| III CFA | Checkpoint Therapeutics | 46 | |
| Yohai CPA | Galmed Pharmaceuticals | 41 | |
| Brian Kevany | Abeona Therapeutics | N/A | |
| Nancy Pecota | Adverum Biotechnologies | 64 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
Management Performance
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.56 |
Calithera Biosciences Leadership Team
Elected by the shareholders, the Calithera Biosciences' board of directors comprises two types of representatives: Calithera Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Calithera. The board's role is to monitor Calithera Biosciences' management team and ensure that shareholders' interests are well served. Calithera Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Calithera Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allison Dillon, VP Strategy | ||
| Susan Demo, VP Operations | ||
| Stephanie Wong, Chief Accounting Officer, Vice President - Finance | ||
| Frank Parlati, VP Research | ||
| Eric Sjogren, Sr. VP of Drug Discovery | ||
| Emil MD, Chief Officer | ||
| Christopher Molineaux, Sr. VP of Devel. | ||
| Susan Molineaux, Co-Founder, CEO and President and Director |
Calithera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Calithera Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | (1.1 M) | ||||
| Shares Outstanding | 4.87 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 26.76 % | ||||
| Number Of Shares Shorted | 417.28 K | ||||
| Price To Earning | (14.08) X | ||||
| Price To Book | 1.86 X | ||||
| Price To Sales | 1.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Calithera Pink Sheet
If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |